Prices plus VAT plus shipping costs
Ready to ship today,
Delivery time appr. 5-8 days
- Order number: 7TM0360N-IC
- Content: 100 µl
- Host: Rabbit
The NK1 antibody is directed against the distal end of the carboxyl-terminal tail of human Tachykinin Receptor 1 (also called Substance P Receptor). It detects selectively the canonical full-length NK1 Tachykinin Receptor. It can be used to detect total NK1 receptors in Western blots independent of phosphorylation. The NK1 antibody can also be used to isolate and enrich NK1 receptors from brain lysates. It also detects NK1 in cultured cells and tissue sections by immunohistochemistry.
| Alternative Names | NK1, SPR, TACR1, Neurokinin Receptor 1, Substance P Receptor |
| IUPHAR Target ID | 360 |
| UniProt ID | P25103 |
| Western Blot (WB) | 1:1000 |
| Immunocytochemistry (ICC) | 1:200 |
| Immunohistochemistry (IHC) | 1:100 |
| Species Reactivity | Human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Immunogen | A synthetic peptide with sequence SSRSDSKTMTESFSFSSNVLS corresponds to amino acids 387-407 of human NK1. |
| Form | Liquid |
| Purification | Antigen affinity chromatography |
| Storage buffer | Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide |
| Storage conditions | short-term 4°C, long-term -20°C |
Figure 1. Immunohistochemical identification of Tachykinin Receptor 1 in pancreatic carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-NK1 (Tachykinin Receptor 1) antibody (7TM0360N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, NK1 receptors were uniformly detected at the plasma membrane of chief cell in the pancreatic carcinoma.
Figure 2. Immunohistochemical identification of Tachykinin Receptor 1 in glioblastoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-NK1 (Tachykinin Receptor 1) antibody (7TM0360N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, NK1 receptors were detected predominantly at the level of plasma membrane in glioblastoma.
Figure 3. Immunohistochemical identification of Tachykinin Receptor 1 in ovarian carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-NK1 (Tachykinin receptor 1) antibody (7TM0360N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, NK1 receptors were detected predominantly at the level of plasma membrane in ovarian carcinoma.
Figure 4. Validation of the Tachykinin Receptor 1 in transfected HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the Tachykinin Receptor 1 (NK1) were lysed and immunoblotted with the anti-NK1 antibody (7TM0360N-IC) at a dilution of 1:1000.
Figure 5. Immunocytochemical identification of Tachykinin Receptor 1 in HEK293 cells. HEK293 cells stably expressing the Tachykinin receptor 1 (NK1) were either not exposed or exposed to 1 μM Substance P for 30 min and immunocytochemically stained with anti-NK1 (non-phospho-Tachykinin receptor 1) antibody (7TM0360N-IC) at a dilution of 1:200. Note, NK1 receptors were confined to the plasma membrane in untreated cells (0 min). NK1 receptors were seen in perinuclear clusters of vesicles after 30 min Substance P exposure.
